Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results

  • Mesia Nin R
  • Bossi P
  • Hansen A
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: Second/third-line treatment (Tx) options are limited for pts with NPC. The efficacy and safety of CC-486 were assessed using Simon's optimal 2-stage design in a phase 2 study. The predefined criterion for advancement to stage 2 (> 4 complete/ partial responses) was not met. Here, we present final results from stage 1. Methods: The single-arm, open-label study (NCT02269943) included pts with locally advanced/metastatic NPC who had ≥1 prior Tx, including ≥1 platinum-containing regimen. Pts received CC-486 300 mg orally on d 1-14 of a 21-d cycle until disease progression/ unacceptable toxicity. The first 6 Asian-Pacific (AP) pts received CC-486 200 mg; if well tolerated, subsequent AP pts received 300 mg. Primary endpoints (per independent reviewer assessment): overall response rate, progression-free survival. Key secondary endpoints: overall survival, disease control rate, safety, pharmacokinetics (PK). Results: Median age of 36 enrolled pts was 54.0 y. Most were male (81%), had ECOG PS of≤1 (97%), and had ≥2 prior systemic anticancer Tx (58%); 36% were AP. Pts received a median of 7.0 Tx cycles; 44% had ≥1 dose interruption and 39% had ≥ 1 dose reduction. 22 pts died: 1 on- and 21 post-Tx (> 28 d after last dose); 18 died due to disease complications. The table shows efficacy outcomes. PK analysis showed rapid absorption; exposure was comparable between doses. However, large inter-pt variability and small pt numbers did not allow definitive conclusions. All 36 safety-evaluable pts had ≥ 1 Tx-emergent adverse event (TEAE). Common TEAEs included vomiting (72%) and nausea (67%). Common grade 3/4 TEAEs included neutropenia (33%) and febrile neutropenia (11%). Conclusions: The safety profile of CC-486 in pts withNPC was consistent with that in other solid tumors and of azacitidine. CC-486monotherapy did not show sufficient clinical activity in the selected pt population to support further development in these pts. (Table Presented) .

Cite

CITATION STYLE

APA

Mesia Nin, R., Bossi, P., Hansen, A., Hsieh, C., Licitra, L. F., Tan, E. H., … Haddad, R. (2018). Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results. Annals of Oncology, 29, viii382. https://doi.org/10.1093/annonc/mdy287.027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free